Avelumab and Merkel Cell Carcinoma: Evaluating the Evidence for Causation

From General Health Communication to Targeted Risk Assessment

General health and science communication has long served as a foundation for public understanding of medical risks, emphasizing the importance of evidence-based information in guiding clinical decisions. Within this legacy framework, discussions of pharmaceutical safety have traditionally focused on broad adverse event profiles, often without deep exploration of specific exposure contexts. As the field evolves, there is growing recognition that certain therapeutic agents require more targeted scrutiny, particularly when their use intersects with rare but serious outcomes. This shift in perspective is exemplified by the transition from general health advisories to focused inquiries into drug-disease associations, where the precise nature of exposure becomes a critical variable. In the domain of mass production—where pharmaceuticals are manufactured, distributed, and administered at scale—the need for granular risk assessment intensifies. Here, the legacy of general health information provides a necessary baseline, but it must be augmented by occupational and clinical exposure analysis. The pivot from broad health context to specific exposure concern is therefore not a departure from scientific rigor, but an extension of it. This transition allows for a more nuanced examination of how a given therapeutic agent, such as an immune checkpoint inhibitor, may be linked to subsequent disease development in exposed populations, without prematurely invoking mechanistic pathways.

Avelumab: Mechanism and Approved Use in Merkel Cell Carcinoma

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication and is approved independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). The disease is characterized by high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Clinical presentation typically involves a rapidly growing, painless, firm, red or purple nodule on sun-exposed skin, often on the head, neck, or extremities. Diagnosis is confirmed by histopathology and immunohistochemistry, showing neuroendocrine differentiation.

Efficacy and Immune-Related Adverse Events of Avelumab

Despite advances in systemic therapy, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors (ICIs) progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Avelumab, as an anti-PD-L1 inhibitor, functions by blocking the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby enhancing the immune system's ability to recognize and attack cancer cells. However, checkpoint inhibitors are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). Reported adverse effects include hypercalcaemia secondary to reactivation of sarcoidosis during avelumab treatment for metastatic MCC, which was managed with corticosteroids to full resolution, allowing avelumab therapy to be safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). Mechanistically, avelumab's immune activation can trigger inflammatory responses that may exacerbate underlying conditions or induce new autoimmune phenomena.

Causation Considerations: Avelumab as Treatment, Not Cause

Regarding causation-related considerations for affected patients, the primary concern is not that avelumab causes de novo Merkel cell carcinoma, but rather that it is used to treat existing MCC. The literature focuses on avelumab's efficacy and safety in MCC patients, including those who become refractory to treatment. For avelumab-refractory patients, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). Studies have explored combination therapy with ipilimumab plus nivolumab in avelumab-refractory MCC, with three out of five patients responding to combined therapy according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). Another multicenter study reported response rates to PD-1/PD-L1 inhibition of up to 62% in metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). These findings indicate that while avelumab is effective for many patients, a subset does not respond or progresses, necessitating alternative treatments. The timeline between exposure and documented harm is relevant to adverse events rather than MCC causation. Immune-related adverse events can occur at any time during avelumab treatment, as illustrated by the case of hypercalcaemia due to sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). The onset of such events is variable and depends on individual patient factors. For MCC progression while on avelumab, the timeline is typically assessed during treatment cycles, with response evaluations conducted per RECIST criteria. Adequacy of warnings regarding avelumab and Merkel cell carcinoma is addressed in prescribing information and clinical guidelines. The drug's approval for metastatic MCC is based on demonstrated efficacy, and warnings focus on immune-related adverse events rather than carcinogenicity. The literature does not suggest that avelumab causes MCC; instead, it is a therapeutic agent for the disease. Therefore, warnings appropriately emphasize monitoring for irAEs and managing treatment-refractory disease. In summary, avelumab is a PD-L1 inhibitor approved for metastatic MCC, with a well-characterized efficacy profile and known immune-related adverse events. The evidence does not support a causal link between avelumab and the development of MCC; rather, it is a treatment for the condition. Causation considerations for affected patients center on treatment response and adverse event management, with timelines for harm related to irAEs rather than MCC induction.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, the medical literature does not support a causal link between avelumab and the development of Merkel cell carcinoma. Avelumab is a treatment for metastatic MCC, not a cause. The drug is an immune checkpoint inhibitor that targets PD-L1 and is approved for treating existing MCC.

What are the main risks associated with avelumab treatment?

The primary risks are immune-related adverse events (irAEs) due to overactivation of the immune system. These can include conditions like hypercalcaemia from sarcoidosis reactivation, as reported in a case study (https://pubmed.ncbi.nlm.nih.gov/31543781/). Patients should be monitored for irAEs during treatment.

What is the prognosis for patients with avelumab-refractory Merkel cell carcinoma?

For patients who do not respond to avelumab, alternative treatments such as combination therapy with ipilimumab plus nivolumab have shown some efficacy, with responses in three out of five patients in one study (https://pubmed.ncbi.nlm.nih.gov/33439294/). However, efficient and safe options remain limited.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.